title: Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice.
abstract: Collagen-induced arthritis in the DBA/1 mouse is an experimental model of human rheumatoid arthritis. To examine the role of leukotrienes in the pathogenesis of this disease, we have developed embryonic stem (ES) cells from this mouse strain. Here, we report that DBA/1 mice made deficient in 5-lipoxygenase-activating protein (FLAP) by gene targeting in ES cells develop and grow normally. Zymosan-stimulated leukotriene production in the peritoneal cavity of these mice is undetectable, whereas they produce substantial amounts of prostaglandins. The inflammatory response to zymosan is reduced in FLAP-deficient mice. The severity of collagen-induced arthritis in the FLAP-deficient mice was substantially reduced when compared with wild-type or heterozygous animals. This was not due to an immunosuppressive effect, because anti-collagen antibody levels were similar in wild-type and FLAP-deficient mice. These data demonstrate that leukotrienes play an essential role in both the acute and chronic inflammatory response in mice.
authors.affiliation: Department of Cancer, Immunology, and Infectious Diseases, Pfizer, Inc., Groton, Connecticut 06340, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Griffiths
authors.forename: M A
authors.initials: MA
authors.lastname: Smith
authors.forename: M L
authors.initials: ML
authors.lastname: Roach
authors.forename: J L
authors.initials: JL
authors.lastname: Stock
authors.forename: E J
authors.initials: EJ
authors.lastname: Stam
authors.forename: A J
authors.initials: AJ
authors.lastname: Milici
authors.forename: D N
authors.initials: DN
authors.lastname: Scampoli
authors.forename: J D
authors.initials: JD
authors.lastname: Eskra
authors.forename: R S
authors.initials: RS
authors.lastname: Byrum
authors.forename: B H
authors.initials: BH
authors.lastname: Koller
authors.forename: J D
authors.initials: JD
authors.lastname: McNeish
mesh_terms: D058927:5-Lipoxygenase-Activating Proteins; D000818:Animals; D000917:Antibody Formation; D001169:Arthritis, Experimental / Q000473:pathology / Q000503:physiopathology* / Q000517:prevention & control; D001798:Blood Proteins / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism* / Q000502:physiology*; D003094:Collagen / Q000276:immunology*; D005260:Female; D006579:Heterozygote; D006801:Humans; D007596:Joints / Q000276:immunology / Q000473:pathology; D015289:Leukotrienes / Q000096:biosynthesis / Q000502:physiology; D008297:Male; D008565:Membrane Proteins / Q000172:deficiency* / Q000378:metabolism* / Q000502:physiology*; D051379:Mice; D008811:Mice, Inbred DBA; D018345:Mice, Knockout; D010529:Peritoneal Cavity; D013234:Stem Cells; D015054:Zymosan / Q000494:pharmacology
chemical_list: D058927:5-Lipoxygenase-Activating Proteins; C548592:ALOX5AP protein, human; C548593:Alox5ap protein, mouse; D001798:Blood Proteins; D002352:Carrier Proteins; D015289:Leukotrienes; D008565:Membrane Proteins; D003094:Collagen; D015054:Zymosan